Menu
  • Join
  • Login
  • Contact
 

Search abstracts


MDMX is a novel therapeutic target in cervical carcinoma by inhibiting p53 function

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: WANG, Hongbo (Yantai, China)
  • Co-author(s): Jingwen Zhang: Key Lab of Molecular Pharmacology and Drug Evaluation, Yantai University, Yantai, China
    Hongbo Wang: Key Lab of Molecular Pharmacology and Drug Evaluation, Yantai University, Yantai, China;Key Lab of Molecular Pharmacology and Drug Evaluation, Yantai University, Yantai, China
    Fenghua Fu: Key lab of Molecular Pharmacology and drug evaluation, Yantai University, Yantai, China
  • Abstract:

    Backgrounds

    Cervical cancer is among the most common malignant tumours and the fourth leading cause of cancer death among women worldwide. MDMX, known as a mean to dampen p53 tumor-suppressor function, has recently been found to be overexpressed in certain types of human cancers. However, the role of MDMX in cervical carcinogenesis remains unclear.

    A

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses